# Jason Rhodes

> Jason Rhodes is a partner at Atlas Venture, a board member and former chairman and founding CEO of Rectify Pharmaceuticals, and chairman and former founding CEO of Dyne Therapeutics. His career spans venture investing at Fidelity Biosciences, business development at Alnylam, executive leadership at Epizyme, and company creation at Atlas, which he joined in 2014. He was also chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020.

- **Role:** Partner at Atlas Venture; Board member and former chairman and founding CEO at Rectify Pharmaceuticals
- **Organizations:** Atlas Venture, Rectify Pharmaceuticals, Dyne Therapeutics, Accent Therapeutics, K36 Therapeutics, KaryoVerse, AAVantgarde Bio, Mithril, Weaver, American Academy in Rome, Vagelos Program in Life Sciences and Management, University of Pennsylvania, Fidelity Biosciences (now F-Prime Capital), Alnylam Pharmaceuticals, Epizyme, Disarm Therapeutics, Generation Bio
- **Education:** BA in History, Yale University, MBA, The Wharton School, University of Pennsylvania
- **Known for:** Helped secure more than $200 million in non-equity funding through Alnylam partnerships and more than $180 million through Epizyme partnerships, as reported at his 2014 Atlas appointment., Part of Epizyme’s executive leadership during its transition from a private research company to a public company; its IPO and follow-on raised $196 million combined., Founding CEO and subsequent chairman of Dyne Therapeutics and Rectify Pharmaceuticals.

## Career timeline

- **Before 2007** — Founder and partner at Fidelity Biosciences; investments included Ironwood, FoldRx and Tetraphase.
- **2007–2010** — Led business development at Alnylam Pharmaceuticals.
- **2010–2014** — Executive at Epizyme, ultimately president and CFO.
- **2014** — Joined Atlas Venture as a partner effective October 1; served as interim CEO of Raze at its October launch.
- **2016–2026** — Generation Bio board member from October 2016 to February 2026; also served as founding CEO.
- **2017–2018** — Founding president and CEO of Dyne from December 2017 to November 2018; became chairman in November 2018.
- **2020** — Disarm, where he was chairman and founding CEO, acquired by Eli Lilly.
- **2021** — Rectify announced a $100 million Series A; Rhodes had moved from founding CEO to executive chair.
- **2022** — Left Replimune’s board in June to focus on increasing Atlas commitments.
- **2026** — Rectify named Constantine Chinoporos executive chairman on July 15; Rhodes continued as board member and former chairman.

## Achievements

- Helped secure more than $200 million in non-equity funding through Alnylam partnerships and more than $180 million through Epizyme partnerships, as reported at his 2014 Atlas appointment.
- Part of Epizyme’s executive leadership during its transition from a private research company to a public company; its IPO and follow-on raised $196 million combined.
- Founding CEO and subsequent chairman of Dyne Therapeutics and Rectify Pharmaceuticals.
- Chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020 for $135 million upfront with additional conditional milestone payments.

## Latest updates

- **2026-07** — Rectify appointed Constantine Chinoporos executive chairman effective July 15, identifying Rhodes as a board member and former chairman.
- **2026-04** — Dyne’s proxy identifies Rhodes as chairman and records the end of his Generation Bio directorship in February 2026.
- **2024-12** — Atlas announced the closing of its $450 million Fund XIV, with Rhodes among its managing partnership.
- **2024-01** — Discussed early-stage investing, market cycles and company creation in a Wharton interview.

## Links

- Website: https://atlasventure.com/team/jason-rhodes/
- LinkedIn: https://www.linkedin.com/in/jason-rhodes-07039/
- Twitter/X: https://x.com/jasonpaulrhodes

---

Profile page: https://yespress.io/jason-rhodes
Published by YesPress — https://yespress.io
Last updated: 2026-10-26